Assessing Octreotide Use in the Treatment of Carcinoid Crises in Patients With Neuroendocrine Tumors

Name: Assessing Octreotide Use in the Treatment of Carcinoid Crises in Patients With Neuroendocrine Tumors
Uploaded: 2021-11-04T15:30:14.503Z
Description: Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.

November 4, 2021

Video

Conference|NANETS Annual Multidisciplinary NET Medical Symposium - North American Neuroendocrine Tumor Society Annual Multidisciplinary NET Medical Symposium

Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, discusses what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.

Pharmacy Times interviewed Rodney Pommier, MD, FACS, professor of surgery, division of surgical oncology, school of medicine, Oregon Health & Science University, on his presentation at the 2021 NANETS Multidisciplinary NET Medical Virtual Symposium discussing a prospective study of carcinoid crisis with no perioperative octreotide.

During the interview, Pommier explained what octreotide is and how it is used to reduce carcinoid crisis rates or treat a crisis.